Alnylam Pharmaceuticals Inc (ALNY)vsJazz Pharmaceuticals PLC (JAZZ)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
JAZZ
Jazz Pharmaceuticals PLC
$189.08
+2.20%
HEALTHCARE · Cap: $11.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Jazz Pharmaceuticals PLC generates 15% more annual revenue ($4.27B vs $3.71B). ALNY leads profitability with a 8.5% profit margin vs -8.3%. JAZZ earns a higher WallStSmart Score of 55/100 (C).
ALNY
Hold49
out of 100
Grade: D+
JAZZ
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for JAZZ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 24.6%
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
3.2% earnings growth
Weak financial health signals
ROE of -8.5% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : JAZZ
The strongest argument for JAZZ centers on PEG Ratio, Price/Book, Operating Margin. Revenue growth of 10.1% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : JAZZ
The primary concerns for JAZZ are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while JAZZ is a turnaround play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.38 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
JAZZ generates stronger free cash flow (297M), providing more financial flexibility.
Bottom Line
JAZZ scores higher overall (55/100 vs 49/100) and 10.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Jazz Pharmaceuticals PLC
HEALTHCARE · BIOTECHNOLOGY · USA
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?